References:
[1] Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx: the journal of the American Society for Experimental NeuroTherapeutics, 2005, 2(1), 3–14. https://doi.org/10.1602/neurorx.2.1.3

[2] Yang Z., Liu Z., Allaker R. P., Rie P., Oxford J., Ahmad Z., et, al., A review of nanoparticle functionality and toxicity on the central nervous system. Journal of the Royal Society, 2010, 74(Suppl 4), S411–S422. https://doi.org/10.1098/rsif.2010.0158.focus

[3] Arvanitis C. D., Ferraro G. B., Jain R. K. . The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nature review, Cancer, 2020, 20(1), 26–41. https://doi.org/10.1038/s41568-019-0205-x

[4] Pardridge W. M.. Drug transport across the blood-brain barrier. Journal of cerebral blood flow and metabolism: J of the IntSociety of Cerebral Blood Flow and Metabolism, 2012, 32(11), 1959–1972. https://doi.org/10.1038/jcbfm.2012.126

[5] Shirke S.N., Mulla J. A.. Intranasal nanoemulsion for brain targeting: A review. Indian Journal of Novel Drug Delivery, 2023, 15(1), 1-1.

[6] Burgess A., Hynynen K.. Drug delivery across the blood-brain barrier using focused ultrasound. Expert opinion on drug delivery, 2014, 11(5), 711–721. https://doi.org/10.1517/17425247.2014.897693

[7] Abbott N. J., Patabendige A.A., Dolman D. E. M.. Structure and function of the blood-brain barrier. Neurobiology of disease, 2010, 37(1), 13–25. https://doi.org/
10.1016/j.nbd.2009.07.030

[8] Hawkins B. T., Davis T. P.. The Blood-Brain Barrier/Neurovascular Unit in Health and Disease. Pharmacol Rev, 2005, 57, 173–185.

[9] Mulla J. A.. Molecular pharmacology of nanocarrier based drug delivery systems: Mechanisms, targets, and therapeutic implications. World Journal of Molecular Pharmacolog, 2024, 1(1), 16-23.

[10] Mulla J. A.. Bridging the disciplines of molecular biology, nanotechnology, and nanomedicine. World Journal of Molecular Biology. 2024, 1(1), 20-5.

[11] Ballabh P., Braun A., Nedergaard M.. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiology of disease, 2004, 16(1), 1–13. https://doi.org/10.1016/j.nbd.2003.12.016

[12] Trotta M., Debernardi F., Caputo O.. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. International journal of pharmaceutics, 2003, 257(1-2), 153–160. https://doi.org/10.1016/s0378-5173(03)00135-2

[13] Liu S., Jin X., Ge Y.. Advances in brain-targeted delivery strategies and natural product-mediated enhancement of blood-brain barrier permeability. Journal of nanobiotechnology, 2025, 23(1), 382. https://doi.org/10.1186/s12951-025-03415-w

[14] Ding S., Khan A. I., Cai X., Song Y.. Overcoming blood-brain barrier transport: Advances in nanoparticle-based drug delivery strategies. Materials today, 2020, 37, 112–125. https://doi.org/10.1016/j.mattod.2020.02.001

[15] Alahmari A.. Blood-Brain Barrier Overview: Structural and Functional Correlation. Neural plasticity, 2021, 6564585. https://doi.org/10.1155/2021/6564585

[16] Mak M., Fung L.. Distribution of drugs following controlled delivery to the brain interstitium. Journal of neuro-oncology, 1995, 26(2), 91–102. https://doi.org/10.1007/BF01060215

[17] Grossman S., Reinhard A. C.. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. Journal of neurosurgery, 1992, 76(4), 640–647. https://doi.org/10.3171/jns.1992.76.4.0640

[18] Rezai A. R., D’Haese P. F., Finomore V., Carpenter J., Ranjan M., Wilhelmsen K., et, al.. Ultrasound Blood-Brain Barrier Opening and Aducanumab in Alzheimer’s Disease. The New England journal of medicine, 2024, 390(1), 55–62. https://doi.org/10.1056/NEJMoa2308719

[19] Li B., Lin Y.. Anchoring Microbubbles on Cerebrovascular Endothelium as a New Strategy Enabling Low-Energy Ultrasound-Assisted Delivery of Varisized Agents Across Blood-Brain Barrier. Advanced science, 2023, 10(33), e2302134. https://doi.org/10.1002/advs.202302134

[20] Kwak G., Grewal A.. Brain Nucleic Acid Delivery and Genome Editing via Focused Ultrasound-Mediated Blood-Brain Barrier Opening and Long-Circulating Nanoparticles. ACS nano, 2024, 18(35), 24139–24153. https://doi.org/10.1021/acsnano.4c05270

[21] Potere N., Del B.. Low Density Lipoprotein Receptor-Related Protein-1 in Cardiac Inflammation and Infarct Healing. Frontiers in cardiovascular medicine, 2019, 6, 51. https://doi.org/10.3389/fcvm.2019.00051

[22] Demeule M., Currie J. C.. Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. Journal of neurochemistry, 2008, 106(4), 1534–1544. https://doi.org/10.1111/j.1471-4159.2008.05492.x

[23] Tamai I., Sai Y.. Structure-internalization relationship for adsorptive-mediated endocytosis of basic peptides at the blood-brain barrier. The Journal of pharmacology and experimental therapeutics, 1997, 280(1), 410–415.

[24] Zheng H., Zhang L.. GCN5targeted dual-modal probe across the blood-brain barrier for borders display in invasive glioblastoma. Nat Commun, 2025, 16, 23-45

[25] Kheradkar W. A., Mulla J. A. S.. Nanosuspension: A Novel Technology for Drug Delivery. Asian Journal of Research in Pharmaceutical Sciences, 2023, 13(2), 106-0,doi: 10.52711/2231-5659.2023.00020

[26] Mulla J. A., Chalke P. M., Londhe S. P., Patil M. A., Nalawade S. N., Sawant R. R.. Design and Optimization of Nanosponges of Poorly Soluble Voriconazole Using Central Composite Design. Indian Journal of Novel Drug Delivery, 2023;15(4), 189-99.

[27] Mhoprekar J. D., Mulla J. A.. Nanosponges drug delivery: A concise review. World Journal of Nanoparticle Research, 2023, 1(1), 17-28.

[28] Mulla J. A.. Nano-based drug delivery systems: A comprehensive review of design, mechanisms and applications. World J Pharm, 2024, 1(1), 1-1.

[29] Date R. B., Mulla J. A. S.. Nanosponges Loaded Hydrogels for Anti-Inflammatory Drug Delivery: Characterization Evaluation and Applications. Asian Journal of Pharmaceutical Research, 2026, 16(1), 27-32.

[30] Kadam S. S., Mulla J. A.. Design, Development and Evaluation of Etodolac Loaded Chitosan based Nanogel for Topical Drug Delivery. Hacettepe University Journal of the Faculty of Pharmacy, 2025, 45(2), 146-61.

[31] Jadhav P., Mulla J. A. S.. Unlocking Nanosponges Potential: An Overview of Formulation Strategies, Assessment Approaches and Emerging applications. Indian Journal of Novel Drug Delivery, 2024, 16(3), 130-136.

[32] Gajbhiye K. R., Gajbhiye V.. Ascorbic acid tethered polymeric nanoparticles enable efficient brain delivery of galantamine: An in vitro – in vivo study. Scientific reports, 2017, 7(1), 11086, https://doi.org/10.1038/s41598-017-11611-4

[33] Patole P. J., Mulla J. A.. Liposomal In Situ Gel: A Novel Approach for the Treatment of Parkinson’s disease via Intranasal Drug Delivery. Research Journal of Pharmaceutical Dosage Forms and Technology, 2025, 17(1), 53-62.

[34] Mulla J. A., Suresh S., Khazi I. A.. Formulation, characterization and in vitro evaluation of methotrexate solid lipid nanoparticles. Research Journal of Pharmacy and Technolog, 2009, 2(4), 685-9.

[35] Panchamukhi S. I., Mulla J. A.. Benzothieno [3, 2‐e][1, 2, 4] triazolo [4, 3‐c] pyrimidines: Synthesis, Characterization, Antimicrobial Activity, and Incorporation into Solid Lipid Nanoparticles. Archiv der Pharmazie, 2011, 344(6), 358-65.

[36] Mulla J. S., Khazi I. M., Sharma N. K., Hiremath S. P., Jamakandi V. G.. Solid lipid nanoparticles: methods of preparation. Indian J Nov Drug Deliv, 2011, 3(3), 170-5.

[37] Maiti D., Inamdar M. N., Almuqbil M., Suresh S., Asdaq S. M., Alshehri S., Al Arfaj S., Alamri A. M.. Evaluation of solid-lipid nanoparticles formulation of methotrexate for anti-psoriatic activity. Saudi Pharmaceutical Journal. 2023, 31(6), 834-44.

[38] Mulla A. S., Shetty N. S., Panchamukhi S. I., Khazi I. A.. Formulation, characterization and in vitro evaluation of novel thienopyrimidies and triazolothienopyrimidies loaded solid lipid nanoparticles. InternationalJournal of Research in Ayurveda and Pharmacy, 2010,192-200

[39] Mulla J. A., Hiremath S. P., Sharma N. K.. Repaglinide loaded solid lipid nanoparticles: design and characterization. RGUHS J Pharm Sci. 2012, 2(4), 41-9

[40] Mulla J. S., Khazi I. M.. Influence of process variables on particle size of solid lipid nanoparticles. Indian Journal of Novel Drug Delivery. 2009, 1(1), 47-9.

[41] Mulla J. A., Khazi M. I., Khan A, Y., Khazi I. A.. Design, Characterization and In vitro Evaluation of Imidazo [2, 1-b][1, 3, 4] thiadiazole Derivative Loaded Solid Lipid Nanoparticles. Drug InventionToday, 2012, 4(8).

[42] Mulla J. S., Khazi I. M., Jamakandi V. G.. Solid lipid nanoparticles: Potential applications. Indian J Nov Drug Deliv, 2010, 2, 82-7.

[43] Mulla J. S., Khazi I. M., Sharma N. K.. Solid lipid nanoparticles: Measures of characterization. Indian Journal of Novel Drug delivery. 2011, 3(4), 259-64.

[44] Agus D. B., Gambhir S. S.. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters. The Journal of clinical investigation, 1997, 100(11), 2842–2848. https://doi.org/10.1172/JCI119832

[45] Kreuter J., Alyautdin R. N.. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain research, 1995, 674(1), 171–174. https://doi.org/10.1016/0006-8993(95)00023-j

[46] Kreuter J., Shamenko D.. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. Journal of drug targeting, 2002, 10(4), 317–325. https://doi.org/10.1080/10611860290031877

[47] Shibata S., Ochi A., Mori K.. Liposomes as carriers of cisplatin into the central nervous system–experiments with 9L gliomas in rats. Neurologia medico-chirurgica, 1990, 30(4), 242–245. https://doi.org/10.2176/nmc.30.242

[48] Enchov R., Bird R., Curtze A. E., Zhou Q.. Lipid Nanoparticles-From Liposomes to mRNA Vaccine Delivery, a Landscape of Research Diversity and Advancement. ACS Nano, 2021,15, 16982–17015.

[49] Gastaldi L., Battaglia L.. Solid lipid nanoparticles as vehicles of drugs to the brain: current state of the art. European journal of pharmaceutics and biopharmaceutics: official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnike. V, 2014, 87(3), 433–444. https://doi.org/10.1016/j.ejpb.2014.05.004

[50] Mulla J. A., Mabrouk M., Choonara Y. E., Kumar P., Chejara D. R., du Toit LC, et. al.. Development of respirable rifampicin-loaded nano-lipomer composites by microemulsion-spray drying for pulmonary delivery. Journal of Drug Delivery Science and Technology, 2017, 41, 13-9.

[51] Mujawar N. K., Mulla J. A. S.. Targeted Drug Delivery: Revolutionizing Breast Cancer Treatment with Lipid Polymer Hybrid Nanoparticles. Research Journal of Pharmacy and Technology, 2025, 18(12), 6129-6136.

[52] Pawar S. L., Mulla J. A. S.. Lipomers as Hybrid Nanocarrier: Innovation in Targeted and Controlled Drug Delivery, Indian Journal of Novel Drug Delivery, 2025, 17(3), 150-164.

[53] Nigavekar S. S., Sung L. Y.. 3H dendrimer nanoparticle organ/tumor distribution. Pharmaceutical research, 2004, 21(3), 476–483. https://doi.org/10.1023/B:PHAM.0000019302.26097.cc

[54] Sela H., Cohen H.. Spontaneous penetration of gold nanoparticles through the blood brain barrier (BBB). Journal of nanobiotechnology, 2015, 13, 71. https://doi.org/10.1186/s12951-015-0133-1

[55] Rahman M. M., Islam M. R.. Recent advancements of nanoparticles application in cancer and neurodegenerative disorders: At a glance. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2022, 153, 113305. https://doi.org/10.1016/j.biopha.2022.113305

[56] Choi M., Ryu J., Vu H. D., Kim D.. Transferrin-conjugated Melittin-loaded l-argininecoated iron oxide nanoparticles for mitigating beta-amyloid pathology of the 5XFAD mouse brain. Int J Mol Sci. 2023, 24(19), 14954.

[57] Agwa M. M., Sabra S.. Lactoferrin coated or conjugated nanomaterials as an active targeting approach in nanomedicine. International journal of biological macromolecules, 2021, 167, 1527–1543. https://doi.org/10.1016/j.ijbiomac.2020.11.107

[58] Kamei N., Ikeda K., Ohmoto Y., Fujisaki S.. Insulin-inspired hippocampal neuron-targeting technology for protein drug delivery. Proc Natl AcadSci U S A, 2024, 121(41).

[59] Golden P. L., Maccagnan T. J., Pardridge W. M.. Human blood-brain barrier leptin receptor. Binding and endocytosis in isolated human brain microvessels. The Journal of clinical investigation, 1997, 99(1), 14–18. https://doi.org/10.1172/JCI119125

[60] Gupta B., Levchenko T. S.. TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncology research, 2007, 16(8), 351–359. https://doi.org/10.3727/000000006783980946

[61] Dunn B., Stein P., Cavazzoni P.. Approval of Aducanumab for Alzheimer Disease-The FDA’s Perspective. JAMA internal medicine, 2021, 181(10), 1276–1278. https://doi.org/10.1001/jamainternmed.2021.4607

[62] Ireson C. R., Kelland L. R.. Discovery and development of anticancer aptamers. Molecular cancer therapeutics, 2006, 5(12), 2957–2962. https://doi.org/10.1158/1535-7163.MCT-06-0172

[63] Xu M., Feng T., Liu B., Qiu F,. Engineered exosomes: desirable target-tracking characteristics for cerebrovascular and neurodegenerative disease therapies. Theranostics, 2021, 11(18), 8926–8944. https://doi.org/10.7150/thno.62330

[64] Naik K. K., Ashok B., Naik N., Mulla J. A., Prakasha A.. DNA binding, anti-inflammatory and analgesic evaluation of metal complexes of N/S/O donor ligands; Synthesis, spectral characterization. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, 2015 ,141, 88-93.

[65] Romano G.. Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy. ISRN oncology, 2012, 616310. https://doi.org/10.5402/2012/616310

[66] Choi K. Y., Liu G., Lee S.. Theranosticnano platforms for simultaneous cancer imaging and therapy: current approaches and future perspectives. Nanoscale, 2012, 4(2), 330–342. https://doi.org/10.1039/c1nr11277e

[67] Dipankar P., Salazaret D.. Artificial intelligence based advancements in nanomedicine for brain disorder management: an updated narrative review. Frontiers in medicine, 2025, 12, 1599340. https://doi.org/10.3389/fmed.2025.1599340

[68] Omuro A., DeAngelis L. M.. Glioblastoma and other malignant gliomas: a clinical review. JAMA, 2013, 310(17), 1842–1850. https://doi.org/10.1001/jama.2013.280319

[69] Karran E., De Strooper B.. The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics. Nature reviews. Drug discovery, 2022, 21(4), 306–318. https://doi.org/10.1038/s41573-022-00391-w

[70] Balestrino R., Schapira A. H.. Parkinson disease. European journal of neurology, 2020, 27(1), 27–42. https://doi.org/10.1111/ene.14108

[71] Staley K.. Molecular mechanisms of epilepsy. Nature neuroscience, 2015, 18(3), 367–372. https://doi.org/10.1038/nn.3947

[72] Spiteri A. G., Wishart C. L., Pamphlett R., Locatelli G.. Microglia and monocytes in inflammatory CNS disease: integrating phenotype and function. Actaneuropathologica, 2022, 143(2), 179–224. https://doi.org/10.1007/s00401-021-02384-2

[73] Mulla J. S., Kapse M. V.. Exploring nanomedicine in cancer: Diagnosis, treatment and its potential applications. IP Journal of Diagnostic Pathology and Oncology, 2024, 9(2), 86-94.

[74] Mujawar N., Mulla J. A. S.. Lipid Hybrid Nanoparticles in Cancer Therapy: A Promising Nanotechnology-Based Drug Delivery System. International Journal of Pharmaceutical Sciences and Drug Research, 2025, 17(4), 371-387.

[75] Zhao L., Li J., Kälviäinen R., Jolkkonen J., Zhao C.. Impact of drug treatment and drug interactions in post-stroke epilepsy. Pharmacology & therapeutics, 2022, 233, 108030. https://doi.org/10.1016/j.pharmthera.2021.108030

[76] Capizzi, A., Woo J., Verduzco-Gutierrez M.. Traumatic Brain Injury: An Overview of Epidemiology, Pathophysiology, and Medical Management. The Medical clinics of North America, 2020, 104(2), 213–238. https://doi.org/10.1016/j.mcna.2019.11.001

[77] Worthington E. N., Hagood J. S.. Therapeutic Use of Extracellular Vesicles for Acute and Chronic Lung Disease. International journal of molecular sciences, 2020, 21(7), 2318. https://doi.org/10.3390/ijms21072318

[78] Paganini C., Capasso Palmiero U.. Scalable Production and Isolation of Extracellular Vesicles: Available Sources and Lessons from Current Industrial Bioprocesses. Biotechnology journal, 2019, 14(10), e1800528. https://doi.org/10.1002/biot.201800528

[79] Bateman R. J., Smith J.. Two Phase 3 Trials of Gantenerumab in Early Alzheimer’s disease. The New England journal of medicine, 2023, 389(20), 1862–1876. https://doi.org/10.1056/NEJMoa2304430

[80] Mariana G., Maria R.. Advancing Brain Targeting: Cost-Effective Surface-Modified Nanoparticles for Faster Market Entry. Pharma, 2025, 17, 661.

[81] Ferrari M.. Nanomedicine and society. ClinPharmacolThe. 2009, 85, 466–467.

[82] Krauze M., Forsayeth J., Park J. W., Bankiewicz K. S.. Real-time imaging and quantification of brain delivery of liposomes. Pharmaceutical research, 2006, 23(11), 2493–2504. https://doi.org/10.1007/s11095-006-9103-5

[83] Sethi B., Kumar V., Mahato K., Mahato R. I.. Recent advances in drug delivery and targeting to the brain. Journal of controlled release: official journal of the Controlled Release Society, 2022, 350, 668–687. https://doi.org/10.1016/j.jconrel.2022.08.051

[84] Chen R., Canales A., Anikeeva P.. Neural Recording and Modulation Technologies. Nature reviews. Materials, 2017, 2(2), 16093. https://doi.org/10.1038/natrevmats.2016.93